# US 11,111,274 B2 · Neutralising antibody against dengue for use in a method of prevention and/or treatment of zika infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,111,274 B2
- Document ID: US11111274B2
- Status: Granted
- Kind: B2
- Application number: 16/308,745
- Filed: 2017-06-09
- Published: 2019-08-22
- Granted: 2021-09-07
- Earliest claimed: 2016-06-10
- Assignees: Institut Pasteur; Imperial College Innovations Limited
- Applicants: Imperial Innovations Ltd; Institut Pasteur
- Inventors: Félix Rey; Giovanna Barba Spaeth; Marie-Christine Vaney; Alexander Rouvinski; Gavin Screaton; Juthathip Mongkolsapaya
- Web page: https://patentgrep.com/patent/US11111274B2

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- C07K 14/1825: {Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue}
- C07K 16/116: Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
- G01N 33/56983: {Viruses}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2770/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24171: Demonstrated in vivo effect
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A flavivirus Envelope Dimer Epitope (EDE) for use in vaccinating an individual against one or more flaviviruses wherein the EDE is a stabilized recombinant flavivirus, optionally dengue virus and/or zika envelope glycoprotein E ectodomain (sE) dimer, wherein the dimer is: covalently stabilized with at least one disulphide inter-chain bond between the two sE monomers, and/or non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain 1 (D1)/domain 3 (D3) linker of each monomer, covalently stabilized with at least one sulfhydryl-reactive crosslinker between the two sE monomers, and/or covalently stabilised by being formed as a single polypeptide chain, optionally with a linker region, optionally a Glycine Serine rich linker region, separating the sE sequences, and/or covalently stabilized by linking the two sE monomers through modified sugars; and/or, wherein the dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides, from any one or two of DENV-1, DENV-2, DENV-3, DENV-4, Zika or other flavivirus; and wherein the one or more flaviviruses is selected from zika virus; zika virus and dengue virus; zika virus and other flaviviruses; flaviviruses other than dengue. The EDE may be a homodimer or heterodimer of native and/or mutant envelope polypeptides, from any one or two of DENV-1, DENV-2, DENV-3, DENV-4 and Zika. An isolated neutralizing antibody or antigen binding fragment thereof directed against the EDE as defined in any one of claims 1 to 29, optionally wherein said antibody or fragment thereof binds the five polypeptide segments of the dengue virus glycoprotein E ectodomain (sE) consisting of the residues 67-74, residues 97-106, residues 307-314, residues 148-159 and residues 243-251, or corresponding residues of the flavivirus or Zika virus glycoprotein E ectodomain, or consisting of Zika PF13 residues 67-77, residues 97-106, residues 313-315, residues 243-253, residue K373 or corresponding residues of the flavivirus glycoprotein E ectodomain, optionally wherein binding is unaffected by presence or absence of dengue N153 (Zika N154) glycan or corresponding residue, for use in a method for prevention and/or treatment of infection by one or more flaviviruses, wherein the one or more flaviviruses is selected from zika virus; zika virus and dengue virus; zika virus and other flaviviruses; flaviviruses other than dengue.

## Claims

### Claim 1

A method for increasing an immune response against one or more flaviviruses in a subject, wherein the one or more flaviviruses is not a dengue virus, the method comprising administering a flavivirus Envelope Dimer Epitope (EDE) to the subject,
wherein the EDE is a stabilized recombinant flavivirus-envelope glycoprotein E ectodomain (sE) dimer, wherein the dimer is:
covalently stabilized with at least one disulphide inter-chain bond between the two sE monomers, and/or
non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain I (DI)/domain III (DIII) linker of each monomer,
covalently stabilized with at least one sulfhydryl-reactive crosslinker between the two sE monomers, and/or
covalently stabilised by being formed as a single polypeptide chain, optionally with a linker region, optionally a Glycine Serine rich linker region, separating the sE sequences, and/or
covalently stabilized by linking the two sE monomers through modified sugars; and/or,
wherein the dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides, from any one or two of DENV-1, DENV-2, DENV-3, DENV-4, Zika or other flavivirus.

### Claim 2 (depends on 1)

The method of claim 1 wherein the dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides, from any one or two of DENV-1, DENV-2, DENV-3, DENV-4 and Zika.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is a human subject, wherein the human subject is a pregnant female.

### Claim 4 (depends on 1)

The method of claim 1, wherein the recombinant sE monomer is selected from the group consisting of
SEQ ID No: 1; SEQ ID No: 2; SEQ ID No: 3; SEQ ID No: 4; SEQ ID No: 5; SEQ ID No: 6; SEQ ID No: 7; SEQ ID No: 8; SEQ ID No: 9;
or a mutant sE thereof having at least one mutation selected among mutations #1 to #18 as set out in.

### Claim 5 (depends on 1)

The method of claim 1, wherein the dimer is: (a) glycosylated at the position corresponding to position 67 of DENV-2 and optionally, at the position corresponding to position 153 of DENV-2 or N154 of Zika PF13 of each sE monomer; or (b) covalently stabilized with at least one, two or three disulphide inter-chain bonds between the two sE monomers.

### Claim 6 (depends on 5)

The method of claim 5, wherein the dimer is:
(a) a homodimer of mutants sE having each the mutation:
(i) #2 corresponding to A259C of DENV-2/A264C of Zika PF13; or mutation #1 corresponding to S255C of DENV-2/S260C of Zika PF13, wherein the residues corresponding to 259C/264C or 255C/260C are linked together through a disulphide inter-chain bond; or
(ii) the mutations #4 corresponding to F108C and T315C of DENV-2/F108C and T321C of Zika PF13, or a homodimer of mutants sE having each the mutations #3 corresponding to L107C of DENV-2 and Zika PF13 and A313C of DENV-2/A319C of Zika PF13, wherein the residues corresponding to 108C and 315C/321C or the residues corresponding to 107C and 313C/319C are linked together through a disulphide inter-chain bond
(b) a heterodimer of a mutant sE having the mutations:
(i) #2 corresponding to A259C of DENV-2/A264C of Zika PF13 and a mutant sE having the mutation #1 corresponding to S255C of DENV-2/S260C of Zika PF13, and wherein the residues corresponding to 259C/264C and 255C/260C are linked together through a disulphide inter-chain bond; or
(ii) #4 corresponding to F108C of DENV-2 and Zika PF13 and mutation #3 corresponding to A313C of DENV-2/A319C of Zika PF13 and a mutant sE having the mutations #3 corresponding to L107C of DENV-2 and Zika PF13 and mutations #4 corresponding to T315C of DENV-2/321C of Zika PF13, and wherein the residues corresponding to 108C and 313C/319C are linked respectively to the residues corresponding to 315C/321C and 107C through a disulphide inter-chain bond between the two sE monomers.

### Claim 7 (depends on 5)

The method of claim 5, wherein the dimer is selected from the group consisting of:
(a) a homodimer of mutants sE having each the mutations #2 corresponding to A259C of DENV-2/A264C of Zika PF13, and/or #4 corresponding to F108C of DENV-2 and Zika PF13 and T315C of DENV-2/T321C of Zika PF13,
(b) a homodimer of mutants sE having each the mutations #1 corresponding to S255C of DENV-2/S260C of Zika PF13, and/or #4 corresponding to F108C of DENV-2 and Zika PF13 and T315C of DENV-2/T321C of Zika PF13,
(c) a homodimer of mutants sE having each the mutations #2 corresponding to A259C of DENV-2/A264C of Zika PF13, and/or #3 corresponding to L107C of DENV-2 and Zika PF13 and A313C of DENV-2/T319C of Zika PF13, and
(d) a homodimer of mutants sE having each the mutations #1 corresponding to S255C of DENV-2/S260C of Zika PF13, and/or #3 corresponding to L107C of DENV-2 and Zika PF13 and A313C of DENV-2/T319C of Zika PF13,
wherein the residues corresponding to 259C/264C, 255C/260C, 108C, 315C/321C, 107C and 313C/319C are linked respectively to the residues 259C/264C, 255C/260C, 315C/321C, 108C, 313C/319C and 107C through disulphide inter-chain bonds.

### Claim 8 (depends on 5)

The method of claim 5, wherein the dimer is a heterodimer of:
a mutant sE having the mutations #2 corresponding to A259C of DENV-2/A264C of Zika PF13, #4 corresponding to F108C of DENV-2 and Zika PF13 and T315C of DENV-2/T321C of Zika PF13 and
a mutant sE having the mutations #1 corresponding to S255C of DENV-2/S260C of Zika PF13, #4 corresponding to F108C of DENV-2 and Zika PF13 and T315C of DENV-2/T321C of Zika PF13, wherein the residues 259C/264C, 108C and 315C/321C are linked respectively to the residues 255C/260C, 315C/321C and 108C through disulphide inter-chain bonds.

### Claim 9 (depends on 5)

The method of claim 5, wherein the dimer is a heterodimer of a mutant sE having the mutations S255C/260C, L107C and A313C/319C and a mutant sE having the mutations A259C/264C, L107C and A313C/319C, and wherein the residues 255C/260C, 107C and 313C/319C are linked respectively to the residues 259C/264C, 313C/319C and 107C through disulphide inter-chain bonds.

### Claim 10 (depends on 1)

The method of claim 1, wherein said sulfhydryl-reactive crosslinker is selected from the group consisting of a maleimide, a haloacetyl, a pyridyl disulfide, a vinyl sulfone, an alkyl halide or an aziridine compound, an acryloyl derivative, an arylating agent, or a thiol-disulfide exchange reagent, and optionally, wherein the maleimide sulfhydryl-reactive crosslinker is BMOE, BMB, BMH, TMEA, BM(PEG)2, BM(PEG)3, BMDB, or DTME.

### Claim 11 (depends on 10)

The method of claim 10, wherein the dimer is: (a) a homodimer of mutant sE having each the mutation corresponding to T262C of DENV-2 or T265C of DENV-2, and the residues corresponding to 262C or 265C are linked together through a sulfhydryl-reactive crosslinker; or (b) a heterodimer of a mutant sE having the mutation corresponding to T/S262C of DENV-2 and a mutant sE having the mutation corresponding to T/A265C of DENV-2, and the residues corresponding to 262C and 265C are linked together through a sulfhydryl-reactive crosslinker.

### Claim 12 (depends on 1)

The method of claim 1, wherein the dimer is a homodimer or a heterodimer of
a mutant sE wherein at least one amino acid residue selected from the group consisting of the amino acid residues corresponding to amino acid residues 1-9, 25-30, 238-282, 96-111 and 311-318 of DENV-2 sE is mutated to cysteine and
a mutant sE wherein at least one amino acid residue selected from the group consisting of the amino acid residues corresponding to amino acid residues 1-9, 25-30, 238-282, 96-111 and 311-318 of DENV-2 sE is mutated to cysteine, and wherein the mutated cystein residues are linked together through a sulfhydryl-reactive crosslinker.

### Claim 13 (depends on 1)

The method of claim 1, wherein one of the recombinant sE or the two recombinant sE have at least one mutation selected from the group consisting of mutations corresponding to H27F, H27W, H244F, H244W and L278F of DENV-2.

### Claim 14 (depends on 1)

The method of claim 1, wherein one of the recombinant sE or the two recombinant sE have at least one mutation selected from the group consisting of mutations corresponding to L292F and L294N of DENV-2.

### Claim 15 (depends on 1)

The method of claim 1, wherein the dimer is a homodimer or heterodimer of mutants sE, wherein:
one sE monomer has at least one mutation which introduces a glycosylation site, and wherein the mutated amino acid residue is glycosylated with a modified sugar bearing an X functional group, and
the other sE monomer has at least one mutation which introduces a glycosylation site, and wherein the mutated amino acid residue is glycosylated with a modified sugar bearing a Y functional group,
and wherein both mutated residues are joined together through the modified sugars by reacting, specifically by click chemistry, the X functional group of the sugar of the first sE monomer with the Y functional group of the sugar of the other sE monomer.

### Claim 16 (depends on 1)

The method of claim 1, wherein the EDE comprises a stabilized recombinant dengue virus envelope glycoprotein E ectodomain (sE) dimer, a dimer of Envelope proteins, or the antigenic portion thereof, or consecutive or non-consecutive residues of the envelope polypeptide dimer, held within a heterologous scaffold protein, optionally wherein the levels of covalent and/or non-covalent bonds between monomers are increased, optionally wherein the EDE is an improved EDE.

### Claim 17 (depends on 1)

The method of claim 1, wherein the EDE comprises one or more of positions corresponding to:
(i) E49, K64, Q77, W101, V122 (DENV-1; K122 DENV-2);
(ii) N134, N153, T155, 1161, A162 (DENV-1; 1162 DENV-2);
(iii) P169 (DENV-1; S169 DENV-2);
(iv) T200 (DENV-1; Q200 DENV-2);
(v) K202 (DENV-1; E202 DENV-2);
(vi) E203, L308 (DENV-1; V308 or I308 DENV-2);
(vii) K310, Q323 (DENV-1; R323 DENV-2);
(viii) W391, F392, of the DENV-1 or DENV-2 polypeptide sequence;
(ix) T49, S64, Q77, W101, S122, N134, N154, T156, K166 T205, N207, N208, F314, K316, E319, W400, H401 of Zika PF13; and/or
one or more of positions corresponding to R2, M68, A69, S70, D71, S72, R73, C74, Q77, D83, V97, D98, R99, W101, G102, N103, G104, C105, G106, L113, K251, R252, Q253, T315, K316, Q331, K373 of Zika PF13; and/or
one or more of positions corresponding to
A71, C105, C74, D154, D249, D271, D309, D362, D98, E148, E311, E44, E71, E84, G102, G104, G106, G152, G156, G28, G29, G374, H158, H27, I113, I308, I46, K246, K247, K310, K323, K325, K47, L113, L45, L82, M278, N103, N153, N362, N67, N83, Q248, Q271, Q325, Q77, R2, R247, R323, R73, R99, S72, S81, T115, T155, T361, T46, T68, T69, T70, T72, V113, V114, V250, V309, V324, V97, W101
of the DENV-2 or DENV-4 polypeptide sequence,
optionally wherein the position corresponding to N153 of DENV-2/N154 Zika PF13 and/or N67 of DENV-2 is glycosylated,
optionally wherein the EDE comprises position W101.

### Claim 18 (depends on 1)

The method of claim 1 wherein the EDE comprises a region centred in a valley lined by the b strand on the domain II side, and the “150 loop” on the domain I side (across from the dimer interface), wherein the 150 loop spans residues 148-159, connecting b-strands E0 and F0 of domain I, and carries the N153 glycan, which covers the fusion loop of the partner subunit in the dimer, optionally wherein the region comprises the b strand (residues 67-74 which bear the N67 glycan), the fusion loop and residues immediately upstream (residues 97-106) and the ij loop (residues 246-249) of the reference subunit, wherein the reference subunit is the subunit which contributes the fusion loop,
optionally wherein the EDE further comprises the 150 loop and the N153 glycan chain of the second subunit,
optionally wherein one or both regions is in a substantially similar spatial configuration to the native region;
or wherein the EDE comprises the Zika PF13 beta strand b of domain II, bcd beta-sheet edge, fusion loop main chain, fusion loop R99 side chain, Q77 side chain, disulphide bond between C74 and C105; beta strand E, K373, charged residues in domain I, kl loop of domain II, or regions corresponding thereto.

### Claim 19 (depends on 1)

The method of claim 1 wherein the EDE is presented as part of a virion or a sub-viral particle or a virus-like particle or a nanoparticle, optionally a self-assembling nanoparticle.

### Claim 20 (depends on 1)

The method of claim 1 wherein the EDE elicits an antibody response once administered to the subject, wherein the antibodies are capable of binding to more than one serotype of flavivirus selected from the group consisting of dengue virus, zika virus, west nile virus, Saint Louis encephalitis virus, Japanese encephalitis virus and Murray Valley encephalitis virus.

### Claim 21 (depends on 1)

The method of claim 1 wherein the EDE is expressed as a single polypeptide, optionally wherein the two envelope monomers are separated by a linker, optionally wherein the linker is Glycine and/or Serine rich.

### Claim 22

An Envelope Dimer Epitope (EDE), wherein the EDE is a stabilized recombinant flavivirus envelope glycoprotein E ectodomain (sE) dimer, wherein the flavivirus is not dengue virus, wherein the dimer is:
covalently stabilized with at least one disulphide inter-chain bond between the two sE monomers, and/or
non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain I (DI)/domain III (DIII) linker of each monomer,
covalently stabilized with at least one sulfhydryl-reactive crosslinker between the two sE monomers, and/or
covalently stabilised by being formed as a single polypeptide chain, optionally with a linker region, optionally a Glycine Serine rich linker region, separating the sE sequences, and/or
covalently stabilized by linking the two sE monomers through modified sugars; and/or,
wherein the dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides of the flavivirus, and optionally, wherein the flavivirus is the Zika virus.

### Claim 23

An Envelope Dimer Epitope (EDE), wherein the EDE is a stabilized recombinant flavivirus envelope glycoprotein E ectodomain (sE) dimer, wherein the flavivirus is not dengue virus, wherein the dimer is:
covalently stabilized with at least one disulphide inter-chain bond between the two sE monomers, and/or
non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain I (DI)/domain III (DIII) linker of each monomer,
covalently stabilized with at least one sulfhydryl-reactive crosslinker between the two sE monomers, and/or
covalently stabilised by being formed as a single polypeptide chain, optionally with a linker region, optionally a Glycine Serine rich linker region, separating the sE sequences, and/or
covalently stabilized by linking the two sE monomers through modified sugars; and/or
wherein the dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides of the flavivirus, and optionally, wherein the flavivirus is the Zika virus,
wherein the recombinant sE monomer is selected from the group consisting of SEQ ID No: 6; No: 7; SEQ ID No: 8 and SEQ ID NO:9.

### Claim 24 (depends on 22)

The EDE of claim 22, wherein the dimer is: (a) glycosylated at the position corresponding to position 67 of DENV-2 and optionally, at the position corresponding to position 153 of DENV-2 or N154 of Zika PF13 of each sE monomer; or (b) covalently stabilized with at least one, two or three disulphide inter-chain bonds between the two sE monomers.

### Claim 25 (depends on 22)

The EDE of claim 22, wherein said sulfhydryl-reactive crosslinker is selected from the group consisting of a maleimide, a haloacetyl, a pyridyl disulfide, a vinyl sulfone, an alkyl halide or an aziridine compound, an acryloyl derivative, an arylating agent, or a thiol-disulfide exchange reagent, and optionally, wherein the maleimide sulfhydryl-reactive crosslinker is BMOE, BMB, BMH, TMEA, BM(PEG)2, BM(PEG)3, BMDB, or DTME.

### Claim 26 (depends on 22)

The EDE of claim 22, wherein the recombinant sE monomer comprises SEQ ID No: 1.

### Claim 27 (depends on 22)

The EDE of claim 22, wherein the dimer is:
(a) a homodimer of mutants sE having each the mutation:
(i) #2 corresponding to A259C of DENV-2/A264C of Zika PF13; or mutation #1 corresponding to S255C of DENV-2/S260C of Zika PF13, wherein the residues corresponding to 259C/264C or 255C/260C are linked together through a disulphide inter-chain bond; or
(ii) the mutations #4 corresponding to F108C and T315C of DENV-2/F108C and T321C of Zika PF13, or a homodimer of mutants sE having each the mutations #3 corresponding to L107C of DENV-2 and Zika PF13 and A313C of DENV-2/A319C of Zika PF13, wherein the residues corresponding to 108C and 315C/321C or the residues corresponding to 107C and 313C/319C are linked together through a disulphide inter-chain bond
(b) a heterodimer of a mutant sE having the mutations:
(i) #2 corresponding to A259C of DENV-2/A264C of Zika PF13 and a mutant sE having the mutation #1 corresponding to S255C of DENV-2/S260C of Zika PF13, and wherein the residues corresponding to 259C/264C and 255C/260C are linked together through a disulphide inter-chain bond; or
(ii) #4 corresponding to F108C of DENV-2 and Zika PF13 and mutation #3 corresponding to A313C of DENV-2/A319C of Zika PF13 and a mutant sE having the mutations #3 corresponding to L107C of DENV-2 and Zika PF13 and mutations #4 corresponding to T315C of DENV-2/321C of Zika PF13, and wherein the residues corresponding to 108C and 313C/319C are linked respectively to the residues corresponding to 315C/321C and 107C through a disulphide inter-chain bond between the two sE monomers.

### Claim 28 (depends on 22)

The EDE if claim 22, wherein the EDE elicits an antibody response once administered to a subject, wherein the antibodies are capable of binding to more than one serotype of flavivirus selected from the group consisting of dengue virus, Zika virus, west nile virus, Saint Louis encephalitis virus, Japanese encephalitis virus and Murray Valley encephalitis virus.